Wall Street brokerages forecast that Celgene Co. (NASDAQ:CELG) will report earnings of $1.92 per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Celgene’s earnings, with estimates ranging from $1.87 to $2.00. Celgene reported earnings of $1.61 per share during the same quarter last year, which suggests a positive year-over-year growth rate of 19.3%. The firm is scheduled to issue its next earnings report before the market opens on Thursday, January 25th.
On average, analysts expect that Celgene will report full year earnings of $7.34 per share for the current financial year, with EPS estimates ranging from $7.30 to $7.44. For the next year, analysts forecast that the business will report earnings of $8.78 per share, with EPS estimates ranging from $8.30 to $9.47. Zacks’ EPS calculations are a mean average based on a survey of research analysts that cover Celgene.
Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The business had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter last year, the firm earned $1.58 earnings per share. Celgene’s quarterly revenue was up 10.2% on a year-over-year basis.
Celgene (CELG) opened at $106.00 on Tuesday. Celgene has a 52 week low of $94.55 and a 52 week high of $147.17. The firm has a market cap of $83,460.00, a price-to-earnings ratio of 25.00, a P/E/G ratio of 0.68 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65.
Several hedge funds and other institutional investors have recently modified their holdings of CELG. Thompson Davis & CO. Inc. grew its holdings in shares of Celgene by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 43 shares during the last quarter. Arcadia Investment Management Corp MI grew its holdings in shares of Celgene by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 400 shares during the last quarter. Robecosam AG acquired a new position in shares of Celgene during the third quarter valued at about $114,000. Guidant Wealth Advisors acquired a new position in shares of Celgene during the third quarter valued at about $119,000. Finally, Capital Bank & Trust Co grew its holdings in shares of Celgene by 166.8% during the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 517 shares during the last quarter. Hedge funds and other institutional investors own 79.85% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Celgene Co. (CELG) Expected to Announce Earnings of $1.92 Per Share” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.chaffeybreeze.com/2018/01/16/celgene-co-celg-expected-to-announce-earnings-of-1-92-per-share.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.